Lyka Labs Ltd

Lyka Labs Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Lyka Labs Ltd

₹ 153 -1.99%
15 Jan - close price
lykalabs.com BSE: 500259 NSE: LYKALABS
About

Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]

Key Points

Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.

Website BSE NSE
  • Market Cap ₹ 550 Cr.
  • Current Price ₹ 153
  • High / Low ₹ 177 / 97.9
  • Stock P/E 174
  • Book Value ₹ 27.7
  • Dividend Yield 0.00 %
  • ROCE 3.53 %
  • ROE -5.07 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is expected to give good quarter

Cons

  • The company has delivered a poor sales growth of 9.45% over past five years.
  • Debtor days have increased from 67.4 to 88.6 days.
  • Working capital days have increased from 36.9 days to 70.7 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
73.89 35.57 35.19 27.49 25.53 17.82 22.24 22.88 27.99 32.56 27.77 30.11 41.16
28.27 22.55 22.59 21.18 20.50 15.61 18.94 20.24 23.82 25.69 25.75 26.40 36.21
Operating Profit 45.62 13.02 12.60 6.31 5.03 2.21 3.30 2.64 4.17 6.87 2.02 3.71 4.95
OPM % 61.74% 36.60% 35.81% 22.95% 19.70% 12.40% 14.84% 11.54% 14.90% 21.10% 7.27% 12.32% 12.03%
-3.20 0.58 -2.27 0.95 0.98 -5.95 0.02 0.38 -0.18 0.54 0.32 0.56 0.03
Interest 5.57 4.64 2.99 2.91 3.03 3.08 2.85 1.35 1.19 1.28 1.07 0.65 0.54
Depreciation 3.52 2.24 9.46 3.59 3.62 3.47 3.47 3.47 3.59 2.84 2.90 1.76 1.76
Profit before tax 33.33 6.72 -2.12 0.76 -0.64 -10.29 -3.00 -1.80 -0.79 3.29 -1.63 1.86 2.68
Tax % 16.98% 6.55% 607.08% 6.58% -46.88% 2.24% 0.00% 7.22% -22.78% 38.60% 28.22% 30.65% 28.36%
28.43 6.09 -15.07 0.60 -0.38 -10.42 -3.01 -1.85 -0.49 1.78 -2.13 1.44 2.10
EPS in Rs 9.91 2.12 -5.25 0.21 -0.13 -3.63 -0.98 -0.56 -0.15 0.54 -0.64 0.40 0.59
Raw PDF
Upcoming result date: 4 February 2025

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Jun 2014 15m Jun 2015 Mar 2016 9m Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
127 119 166 130 110 60 71 61 86 194 93 111 132
99 111 139 110 87 63 73 65 67 93 76 95 114
Operating Profit 28 8 28 20 23 -4 -2 -4 20 101 17 16 18
OPM % 22% 7% 17% 16% 21% -6% -3% -6% 23% 52% 18% 14% 13%
3 25 4 8 -2 4 1 -30 0 -4 -4 1 1
Interest 19 27 24 15 19 10 7 20 26 20 12 5 4
Depreciation 12 9 11 9 10 11 7 8 8 17 14 13 9
Profit before tax 0 -3 -3 4 -8 -20 -15 -62 -14 59 -13 -1 6
Tax % 0% 45% 31% -5% -19% -5% -59% 1% -29% 35% -0% 182%
-1 -5 -5 4 -7 -19 -6 -63 -10 38 -13 -3 3
EPS in Rs -0.33 -3.05 -2.29 1.67 -2.51 -6.14 -1.97 -21.10 -4.03 13.59 -4.30 -0.75 0.89
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 9%
3 Years: 9%
TTM: 45%
Compounded Profit Growth
10 Years: %
5 Years: 7%
3 Years: 19%
TTM: 138%
Stock Price CAGR
10 Years: 16%
5 Years: 48%
3 Years: -14%
1 Year: 25%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: -5%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 22 22 22 22 22 28 28 29 29 29 31 33 36
Reserves 44 30 20 22 16 21 15 -43 -54 -15 15 35 63
127 164 137 121 126 113 96 141 163 130 75 59 35
96 113 100 77 88 67 76 73 52 42 31 30 34
Total Liabilities 289 329 279 242 252 229 216 200 190 186 152 157 168
93 162 122 104 133 116 108 105 98 94 68 58 58
CWIP 47 22 27 30 24 28 31 28 26 18 16 23 28
Investments 6 0 0 0 0 0 0 0 0 0 0 0 0
143 145 130 107 94 85 77 68 66 74 67 76 83
Total Assets 289 329 279 242 252 229 216 200 190 186 152 157 168

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
11 89 27 12 31 11 27 5 9 79 9 2
5 -57 37 17 -13 -3 -4 -0 -0 -6 7 -9
-13 -26 -60 -30 -19 -10 -23 3 -12 -63 -22 2
Net Cash Flow 3 6 4 -1 -0 -3 -1 9 -3 10 -5 -6

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Jun 2014 Jun 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 211 209 124 121 97 125 75 48 37 35 79 89
Inventory Days 99 91 77 56 90 139 65 69 41 56 68 78
Days Payable 236 363 220 218 266 301 216 192 141 96 91 98
Cash Conversion Cycle 73 -64 -18 -41 -79 -37 -75 -76 -63 -5 55 68
Working Capital Days 96 -106 -88 -75 -191 -456 -181 -156 -71 6 34 71
ROCE % 10% 2% 10% 7% 9% -8% -5% -6% 10% 61% 5% 4%

Shareholding Pattern

Numbers in percentages

Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
47.79% 47.80% 47.58% 47.58% 51.00% 54.58% 54.81% 54.81% 54.81% 58.11% 58.11% 58.11%
1.12% 0.76% 0.57% 0.37% 0.18% 0.17% 0.18% 0.17% 0.17% 0.15% 0.15% 0.15%
1.19% 3.99% 4.00% 4.00% 3.74% 0.41% 0.41% 0.62% 0.81% 0.75% 0.66% 0.66%
49.89% 47.45% 47.85% 48.05% 45.08% 44.84% 44.61% 44.41% 44.21% 40.99% 41.08% 41.07%
No. of Shareholders 26,22026,96928,43328,51526,82027,20226,65226,42225,71725,71628,94329,099

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings